Amneal Pharmaceuticals, Inc. Class A AMRX 深 滬
已收盤 09-19 16:00:00 美东时间
8.81
+0.100
+1.15%
華盛通- 最 高8.8555
- 今 開8.85
- 成交量 91.95万股
- 最 低 8.68
- 昨 收 8.71
- 總市值 27.05亿
- 52周最高 8.905
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 3.36
- 委 比 -93.81%
- 總股本 3.07亿
- 歷史最高 24.48
- 量 比 0.92
- 振 幅 2.01%
- 歷史最低 1.24
- 每 手 1
- 風險率 1.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
J.P. Morgan reevaluated its coverage of the North American specialty pharma space on Friday, downgrading the generic drugmaker Organon (NYSE:OGN) and upgrading its smaller peer Amneal Pharmaceuticals ...
09-06 20:39
快讯 | Amneal Pharmaceuticals公司预计在2024年第四季度推出丙泊酚。
Amneal Pharmaceuticals Inc - Expects to Launch Propofol in Q4 of 2024
08-20 20:01
FDA批准Amneal Pharmaceuticals(AMRX.US)缓释帕金森病口服疗法
美国FDA已批准Crexont（卡比多巴和左旋多巴）缓释胶囊上市，用于治疗帕金森病（PD）
08-17 07:44
Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $10
Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $9 to $10.
08-12 20:50
快讯 | amneal pharmaceuticals股价在盘前上涨3％，公司提高2024财年的预测指导
Amneal Pharmaceuticals up 3% Premarket After Co Raises FY 2024 Guidance
08-09 19:16
Amneal Expects 2024 Revenues Of $2.70B-$2.80B Versus Prior Guidance Of $2.55B-$2.65B And Consensus Of $2.646B
Raising Full Year 2024 GuidanceThe Company is raising its previously provided full year 2024 guidance. Updated GuidancePrior GuidanceNet revenue$2.70 billion - $2.80 billion$2.55 billion - $2.65 billionAdjusted
08-09 18:09
快讯 | Amneal制药公司第二季度每股收益预期为0.14美元，收入预期为6.581亿美元--伦敦证券交易所IBES数据
Amneal Pharmaceuticals Inc Q2 Shr View $0.14, Rev View $658.1 Mln -- LSEG IBES ...
08-09 18:07
快讯 | Amneal制药公司 - 现预计2024财年的净营业收入为 27亿美元 - 28亿美元。
Amneal Pharmaceuticals Inc -Now Sees FY 2024 Net Revenue$2.70 Bln - $2.80 Bln
08-09 18:06
快讯 | Amneal制药公司-现在预计2024财年调整后每股收益为0.57-0.63美元。
Amneal Pharmaceuticals Inc - Now Sees FY 2024 Adj Shr $0.57 - $0.63
08-09 18:06
